The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
- PMID: 25358689
- PMCID: PMC4293246
- DOI: 10.1158/2159-8290.CD-14-0863
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
Abstract
We examined the immune microenvironment of primary colorectal cancer using immunohistochemistry, laser capture microdissection/qRT-PCR, flow cytometry, and functional analysis of tumor-infiltrating lymphocytes. A subset of colorectal cancer displayed high infiltration with activated CD8(+) cytotoxic T lymphocyte (CTL) as well as activated Th1 cells characterized by IFNγ production and the Th1 transcription factor TBET. Parallel analysis of tumor genotypes revealed that virtually all of the tumors with this active Th1/CTL microenvironment had defects in mismatch repair, as evidenced by microsatellite instability (MSI). Counterbalancing this active Th1/CTL microenvironment, MSI tumors selectively demonstrated highly upregulated expression of multiple immune checkpoints, including five-PD-1, PD-L1, CTLA-4, LAG-3, and IDO-currently being targeted clinically with inhibitors. These findings link tumor genotype with the immune microenvironment, and explain why MSI tumors are not naturally eliminated despite a hostile Th1/CTL microenvironment. They further suggest that blockade of specific checkpoints may be selectively efficacious in the MSI subset of colorectal cancer.
Significance: The findings reported in this article are the first to demonstrate a link between a genetically defined subtype of cancer and its corresponding expression of immune checkpoints in the tumor microenvironment. The mismatch repair-defective subset of colorectal cancer selectively upregulates at least five checkpoint molecules that are targets of inhibitors currently being clinically tested.
©2014 American Association for Cancer Research.
Figures
Comment in
-
The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy.Cancer Discov. 2015 Jan;5(1):16-8. doi: 10.1158/2159-8290.CD-14-1397. Cancer Discov. 2015. PMID: 25583798 Free PMC article.
Similar articles
-
The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy.Cancer Discov. 2015 Jan;5(1):16-8. doi: 10.1158/2159-8290.CD-14-1397. Cancer Discov. 2015. PMID: 25583798 Free PMC article.
-
New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.Gastric Cancer. 2019 Jan;22(1):77-90. doi: 10.1007/s10120-018-0836-8. Epub 2018 May 19. Gastric Cancer. 2019. PMID: 29779068
-
Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.J Exp Clin Cancer Res. 2019 Aug 20;38(1):364. doi: 10.1186/s13046-019-1372-z. J Exp Clin Cancer Res. 2019. PMID: 31429779 Free PMC article.
-
Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?Bull Cancer. 2019 Feb;106(2):105-113. doi: 10.1016/j.bulcan.2018.08.007. Epub 2018 Oct 17. Bull Cancer. 2019. PMID: 30342749 Review.
-
Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.Front Immunol. 2022 Jan 14;12:808964. doi: 10.3389/fimmu.2021.808964. eCollection 2021. Front Immunol. 2022. PMID: 35095898 Free PMC article. Review.
Cited by
-
Evaluation of the efficacy and safety of first- and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta-analysis based on randomized controlled trials.Front Immunol. 2024 Sep 18;15:1439624. doi: 10.3389/fimmu.2024.1439624. eCollection 2024. Front Immunol. 2024. PMID: 39359729 Free PMC article.
-
Clinicopathological Significance of Defective DNA Mismatch Repair in Endometrial Carcinoma: A Single-Center Study From Bahrain.Cureus. 2024 Aug 20;16(8):e67332. doi: 10.7759/cureus.67332. eCollection 2024 Aug. Cureus. 2024. PMID: 39301379 Free PMC article.
-
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.Nat Med. 2024 Sep 15. doi: 10.1038/s41591-024-03250-w. Online ahead of print. Nat Med. 2024. PMID: 39278994
-
Mutational Signatures in Colorectal Cancer: Translational Insights, Clinical Applications, and Limitations.Cancers (Basel). 2024 Aug 24;16(17):2956. doi: 10.3390/cancers16172956. Cancers (Basel). 2024. PMID: 39272814 Free PMC article. Review.
-
Comprehensive Analysis of Microsatellite Instability in Canine Cancers: Implications for Comparative Oncology and Personalized Veterinary Medicine.Animals (Basel). 2024 Aug 27;14(17):2484. doi: 10.3390/ani14172484. Animals (Basel). 2024. PMID: 39272269 Free PMC article.
References
-
- Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. - PubMed
-
- Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4. - PubMed
-
- Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011;71:1263–71. - PubMed
-
- Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–11. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials